News Releases

News Releases

February 18, 2021
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021.
January 11, 2021
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its public offering of 9,200,000 shares of its common stock at a public offering price of $24.50 per
January 6, 2021
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per
January 5, 2021
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan.
January 4, 2021
Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles Well tolerated at all dose levels in mice and non-human primates Company on track to select development candidate for hemophilia A and begin IND-enabling studies this year, submit IND in 2022 Webcast
cross